AXALAP: Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer (clinicaltrials.gov) - Sep 3, 2026 - P1 | N=20 | Recruiting | Sponsor: Dana-Farber Cancer Institute | Trial primary completion date: Sep 2026 ➔ May 2027
Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • HER-2 • PGR
|